Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label AASLD 2014. Show all posts
Showing posts with label AASLD 2014. Show all posts
Friday, December 12, 2014

Summary from AASLD 2014 for Hepatitis C - Main points of discussion with current HCV therapy

›
Summary from AASLD 2014 for Hepatitis C Boston 7-11 November 2014 Feedback from the real-world: do HCV cure rates in real-life patient co...
Monday, November 17, 2014

AASLD - Investigational HCV Combo Delivers in Differing Groups

›
Investigational HCV Combo Delivers in Differing Groups Published: Nov 16, 2014 By Ed Susman, Contributing Writer, MedPage Today Reviewed by ...
1 comment:
Saturday, November 15, 2014

Weekend Reading - AASLD 2014: Overview with expert commentary on key studies presented at the meeting

›
AASLD 2014: Overview with expert commentary on key studies presented at the meeting *Updated Nov 16 to include HCV Advocate's Mid-Mo...
Friday, November 14, 2014

It’s Here: CCO’s Official Conference Coverage of AASLD 2014‏

›
Official Conference Coverage of the 2014 Annual Meeting of the American Association for the Study of Liver Diseases Capsule Summaries ...

VIDEO: Hepatitis C screening rises, but where are the positive cases?

›
VIDEO: Hepatitis C screening rises, but where are the positive cases? By: PATRICE WENDLING, Family Practice News Digital Network  NOVEMBE...

The Post AASLD Annual Meeting Hepatitis C Landscape

›
Investment Commentary @ Seeking Alpha The Post AASLD Annual Meeting Hepatitis C Landscape Leonard Yaffe Summary Advances in efficacy,...
Wednesday, November 12, 2014

Merck To Submit NDA For Grazoprevir/Elbasvir in 2015

›
Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting ® and Published in The Lancet First Wav...
Tuesday, November 11, 2014

AASLD-Merck C-WORTHy Results/Grazoprevir/Elbasvir in Geno 1 Treatment-Naïve and Difficult-to-Cure Patients

›
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Trea...

AASLD-Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment

›
Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment -- ...
1 comment:

Gilead Announces Sofosbuvir Plus GS-5816 SVR12 Rates Across Multiple HCV Genotypes --

›
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C ...

AASLD Conference Reports: HCV Data, slide presentations categorized by genotype and pharmaceutical company

›
65th Annual Meeting of the American Association for the Study of Liver Diseases Comprehensive data  investigating HCV  interferon-fre...

AASLD - AbbVie Results PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients

›
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 - Results demons...

AASLD - AbbVie Results Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I)

›
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipient...

AASLD - BMS Announces High Cure Rates With daclatasvir (DCV) in combination with sofosbuvir (SOF)

›
BMS Announces High Cure Rates for Hepatitis C Drug Mon, 11/10/2014 - 10:42am Bristol-Myers Squibb announced late-breaking data from the lan...

AASLD- Achillion Reports 100% SVR12 With ACH-3102 and Sovaldi

›
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD) Achillion Achieves 100% SVR12 i...